False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: European Journal of Nuclear Medicine and Molecular Imaging, 47, 8, S. 2044-2046
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2020
- Event
-
Veröffentlichung
- (who)
-
Springer Science and Business Media LLC
- (when)
-
2020
- Creator
-
Hartrampf, Philipp E.
Seitz, Anna Katharina
Krebs, Markus
Buck, Andreas K.
Lapa, Constantin Frederik Victor
- DOI
-
10.1007/s00259-019-04645-5
- URN
-
urn:nbn:de:bvb:384-opus4-873451
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:43 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hartrampf, Philipp E.
- Seitz, Anna Katharina
- Krebs, Markus
- Buck, Andreas K.
- Lapa, Constantin Frederik Victor
- Universität Augsburg
- Springer Science and Business Media LLC
Time of origin
- 2020
Other Objects (12)
![Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy](/assets/placeholder/searchResultMediaUnknown.png)
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Die sekundäre Lymphadenektomie nach 68Ga-PSMA oder 18F-FEC PET/CT für das isolierte Lymphknotenrezidiv bei Patienten mit Prostatakarzinom
Vergleich zwischen der 18F-rhPSMA-7.3 PET/CT- und CT-Schnittbildgebung für das primäre N-Staging beim Prostatakarzinom
Intraindividual comparison between [18F] PSMA-1007 PET/CT and multiparametric MRI for radiotherapy planning in primary prostate cancer patients
Test–retest repeatability of organ uptake on PSMA-targeted 18F-DCFPyL PET/CT in patients with prostate cancer
Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer
Analyse der Biodistribution und Detektionsrate der [18F]-siPSMA-14-PET/CT- Bildgebung bei Patienten mit Prostatakarzinom im Primär- und Restaging
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Die sekundäre Lymphadenektomie nach 68Ga-PSMA oder 18F-FEC PET/CT für das isolierte Lymphknotenrezidiv bei Patienten mit Prostatakarzinom
Vergleich zwischen der 18F-rhPSMA-7.3 PET/CT- und CT-Schnittbildgebung für das primäre N-Staging beim Prostatakarzinom
Intraindividual comparison between [18F] PSMA-1007 PET/CT and multiparametric MRI for radiotherapy planning in primary prostate cancer patients
Test–retest repeatability of organ uptake on PSMA-targeted 18F-DCFPyL PET/CT in patients with prostate cancer
Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer
Analyse der Biodistribution und Detektionsrate der [18F]-siPSMA-14-PET/CT- Bildgebung bei Patienten mit Prostatakarzinom im Primär- und Restaging
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Diagnostic performance of [18f]fluorocholine and [68ga]ga-psma pet/ct in prostate cancer: a comparative study
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Die sekundäre Lymphadenektomie nach 68Ga-PSMA oder 18F-FEC PET/CT für das isolierte Lymphknotenrezidiv bei Patienten mit Prostatakarzinom
Vergleich zwischen der 18F-rhPSMA-7.3 PET/CT- und CT-Schnittbildgebung für das primäre N-Staging beim Prostatakarzinom
Intraindividual comparison between [18F] PSMA-1007 PET/CT and multiparametric MRI for radiotherapy planning in primary prostate cancer patients
Test–retest repeatability of organ uptake on PSMA-targeted 18F-DCFPyL PET/CT in patients with prostate cancer
Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer